precisionmedicineonline19h
Maze Therapeutics Doses First Patient in Phase II APOL1 Inhibitor Kidney Disease Trial
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
Maze Therapeutics begins Phase 2 trial for kidney disease drug
Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...
Health Affairs22h
Addressing The Harmfully Slow Uptake Of Race-Neutral Kidney Function Tests
A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...
Maze Therapeutics doses first patient in Phase 2 HORIZON trial
Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...